AstraZeneca's asthma drug Tezspire meets all goals in late-stage esophagitis trial
27/08/2026 07:08
AstraZeneca's asthma drug Tezspire meets all goals in late-stage esophagitis trial Aug 27 (Reuters) - AstraZeneca AZN.L said on Thursday its asthma drug, Tezspire, developed with Amgen AMGN.O, met its main and secondary goals in a late-stage trial for treating eosinophilic esophagitis, a chronic inflammatory disorder of the esophagus.
(Reporting by Raechel Thankam Job in Bengaluru; Editing by Mrigank Dhaniwala)
Recent news on Amgen
See all newsUS RESEARCH ROUNDUP-Apple, Kaiser Aluminum, Reliance
Brief: Amgen Says Imdelltra Combo Reduced Risk Of Death By 58% In First-Line Lung Cancer
Corrected: Amgen drug combined with immunotherapy extends survival in lung cancer trial
US RESEARCH ROUNDUP- Amgen, Lockheed Martin, Norfolk Southern
Eli Lilly hits record high as healthcare stocks rally